{"entity":{"id":"immunopeptidomics","kind":"term","name":"Immunopeptidomics","aka":[],"tldr":"This laboratory approach identifies peptides recovered with immune display molecules. It supplies evidence about peptide presentation in the material that was analyzed.","summary":"A primary melanoma study used mass spectrometry to identify HLA-associated peptides from native tumor tissue and then evaluated selected mutated peptides with immune assays. This is stronger evidence of natural presentation in the sampled material than a binding prediction alone. The analytical observation still has a defined specimen and workflow. It does not automatically establish the abundance of a ligand on every cancer cell, receptor recognition or a treatment effect. A published protocol isolates MHC-peptide complexes by immunoaffinity capture, dissociates the peptides by acid denaturation, fractionates them by HPLC and identifies them by nano-UPLC tandem mass spectrometry, from cell lines and tissues (Purcell and colleagues, 2019). Capture starts from mild-detergent solubilised lysates (Chong and colleagues, 2018; Sarkizova and colleagues, 2020 immunoprecipitated HLA from soluble lysates), so a lysate is not a surface-only survey, and in multi-allele samples a peptide was assigned to the best-scoring allele or alleles by computation (Sarkizova and colleagues, 2020). Identification depends on the analysis: a deep-learning model trained on more than 300,000 synthetic peptides improved HLA peptide identification up to 7-fold and indicated that 87 per cent of the proposed proteasomally spliced HLA peptides may be incorrect (Wilhelm and colleagues, 2021). A quantitative tissue study isolated peptide-HLA complexes from snap-frozen tissue and used formalin-fixed paraffin-embedded blocks only for histology (Science Translational Medicine, 2022).","asOf":"2026-11-10","links":[{"label":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.","url":"https://doi.org/10.1038/ncomms13404"},{"label":"Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction.","url":"https://doi.org/10.1016/j.cell.2020.09.015"},{"label":"Purcell et al., Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics (Nature Protocols 2019)","url":"https://doi.org/10.1038/s41596-019-0133-y"},{"label":"Chong et al., High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferon-gamma-Mediated Remodeling of the Human Leukocyte Antigen Self-Peptidome (Molecular and Cellular Proteomics 2018)","url":"https://doi.org/10.1074/mcp.TIR117.000383"},{"label":"Wilhelm et al., Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics (Nature Communications 2021)","url":"https://doi.org/10.1038/s41467-021-23713-9"},{"label":"Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy (Science Translational Medicine 2022)","url":"https://doi.org/10.1126/scitranslmed.abo6135"},{"label":"A large peptidome dataset improves HLA class I epitope prediction across most of the human population (Nature Biotechnology 2020)","url":"https://doi.org/10.1038/s41587-019-0322-9"}],"tags":[],"related":["immunopeptidome","peptide-hla-binding-prediction","binding-presentation-recognition","finite-tissue-budget"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Reading guide (OnCo inference). In a mixed specimen a recovered HLA-associated peptide does not reveal its cell of origin or its abundance on living cell surfaces. Non-detection does not show biological absence: it also reflects capture, allele coverage, the searchable sequence set and instrument and software sensitivity, and detection does not show safe tumour recognition. No source read here establishes that formalin-fixed tissue is usable for an assay validated on cells or frozen tissue; the lesson's statement that one protocol proposed an adaptation could not be checked (publisher page unavailable), so that claim is withheld and compatibility must be shown for the named method.","Fictional worked example. A specimen yields peptide A but not peptide B. A has measured support in that preparation. For B, ask whether its allele was recovered, whether the altered sequence was searchable and whether sensitivity was adequate; 'A detected, B absent everywhere' is stronger than the experiment supports. If B is simply missing from the search database it could not have been identified as configured, so its absence is not a clean biological negative, and correcting the database does not by itself guarantee recovery or prove natural display.","Reading guide: binding prediction estimates a model output, whereas immunopeptidomics identifies recovered peptides, and total-protein measurements are a different question from HLA-associated fragments (a protein can be abundant without any of its peptides being displayed, an inference); presentation, immune response and efficacy are three separate claims.","Measurement card in words (a reading guide). Input: which tissue preparation and preservation are compatible, and how much material is consumed. Output and units: peptide identities and unique-sequence counts; instrument intensities are method-dependent and not copies per cell. Identification threshold: the sequence database, the false-discovery rule (spectrum or peptide level) and the supporting spectra. Coverage: which HLA classes and alleles were captured and which allele assignments were measured or inferred. Material and cost: protocol-specific input, preservation, consumption, turnaround and analysis cost, requested before a scarce specimen is used. Validation: recovery, reproducibility and reference-peptide checks for the method. Failure modes: low input, poor recovery, mixed cell populations, database gaps and wrong sequence assignments. Limits: non-detection does not prove absence and detection does not prove safe recognition; there is no universal tissue requirement or detection threshold."],"category":"Methods and models"},"route":"/terms/immunopeptidomics/","neighbours":{"term":[{"id":"finite-tissue-budget","kind":"term","name":"Finite tissue and specimen allocation","route":"/terms/finite-tissue-budget/"},{"id":"immune-product-evidence","kind":"term","name":"Immune measurements and product evidence","route":"/terms/immune-product-evidence/"},{"id":"immunopeptidome","kind":"term","name":"Immunopeptidome","route":"/terms/immunopeptidome/"},{"id":"neoantigen","kind":"term","name":"Neoantigen","route":"/terms/neoantigen/"},{"id":"binding-presentation-recognition","kind":"term","name":"Peptide binding, presentation and immune recognition","route":"/terms/binding-presentation-recognition/"},{"id":"peptide-hla-binding-prediction","kind":"term","name":"Peptide-HLA binding and ligand prediction","route":"/terms/peptide-hla-binding-prediction/"}],"pathway":[{"id":"antigen-presentation-immunoediting","kind":"pathway","name":"Antigen presentation & immune editing","route":"/pathways/antigen-presentation-immunoediting/"}]}}